The pre‐ and post‐authorisation data published by the European medicines agency on the use of biologics during pregnancy and lactation
Identifieur interne : 000088 ( Main/Exploration ); précédent : 000087; suivant : 000089The pre‐ and post‐authorisation data published by the European medicines agency on the use of biologics during pregnancy and lactation
Auteurs : N. Ghalandari ; R. J. E. M. Dolhain ; J. M. W. Hazes ; C. L. E. Siezen ; J. W. Van Der Laan ; H. J. M. J. Crijns ; E. P. Van Puijenbroek ; C. J. Van Der WoudeSource :
- British Journal of Clinical Pharmacology [ 0306-5251 ] ; 2020.
Abstract
The effects of biologics on reproduction/lactation are mostly unknown although many patients that receive biologics are women of reproductive age. The first objective of this study was to investigate the publicly available data on pregnancy/lactation before and after marketing authorization in Europe of biologics for the indications of rheumatologic inflammatory autoimmune diseases and inflammatory bowel disease. Secondary objectives included the assessment of the clinical relevance of the provided data and comparison of initial and post‐authorization data.
Initial and post‐authorization data were extracted from the European Public Assessment Reports and the latest versions of Summary of Product Characteristics using publicly available documents on the European Medicines Agency's website. Four sections were categorized regarding pregnancy outcomes: pre‐clinical/animal studies, human female fertility, pregnancy‐related outcomes and congenital malformations in the human fetus. Three sections were categorized regarding lactation outcomes: pre‐clinical/animal studies, excretion in human breast milk and absorption in children through breastfeeding. The clinical applicability of each category was scored by specified criteria, based on scientific literature, and further as defined by the authors.
For the 16 included biologics, post‐authorization data were delivered only for adalimumab, certolizumab pegol, etanercept and infliximab. For the 12 remaining biologics limited data on pregnancy and lactation during the post‐marketing period of 2–21 years were available.
In this article several suggestions are provided for improving a multidisciplinary approach to these issues. The initiation of suitable registries by marketing authorization holders and data transparency for clinicians and academics are highly endorsed.
Url:
DOI: 10.1111/bcp.14145
PubMed: 31633830
PubMed Central: 7080638
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000971
- to stream Pmc, to step Curation: 000971
- to stream Pmc, to step Checkpoint: 000044
- to stream Ncbi, to step Merge: 002463
- to stream Ncbi, to step Curation: 002463
- to stream Ncbi, to step Checkpoint: 002463
- to stream Main, to step Merge: 000088
- to stream Main, to step Curation: 000088
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The pre‐ and post‐authorisation data published by the European medicines agency on the use of biologics during pregnancy and lactation</title><author><name sortKey="Ghalandari, N" sort="Ghalandari, N" uniqKey="Ghalandari N" first="N." last="Ghalandari">N. Ghalandari</name><affiliation><nlm:aff id="bcp14145-aff-0001"></nlm:aff></affiliation><affiliation><nlm:aff id="bcp14145-aff-0002"></nlm:aff></affiliation><affiliation><nlm:aff id="bcp14145-aff-0005"></nlm:aff></affiliation></author><author><name sortKey="Dolhain, R J E M" sort="Dolhain, R J E M" uniqKey="Dolhain R" first="R. J. E. M." last="Dolhain">R. J. E. M. Dolhain</name><affiliation><nlm:aff id="bcp14145-aff-0001"></nlm:aff></affiliation><affiliation><nlm:aff id="bcp14145-aff-0005"></nlm:aff></affiliation></author><author><name sortKey="Hazes, J M W" sort="Hazes, J M W" uniqKey="Hazes J" first="J. M. W." last="Hazes">J. M. W. Hazes</name><affiliation><nlm:aff id="bcp14145-aff-0001"></nlm:aff></affiliation><affiliation><nlm:aff id="bcp14145-aff-0002"></nlm:aff></affiliation><affiliation><nlm:aff id="bcp14145-aff-0005"></nlm:aff></affiliation></author><author><name sortKey="Siezen, C L E" sort="Siezen, C L E" uniqKey="Siezen C" first="C. L. E." last="Siezen">C. L. E. Siezen</name><affiliation><nlm:aff id="bcp14145-aff-0002"></nlm:aff></affiliation></author><author><name sortKey="Van Der Laan, J W" sort="Van Der Laan, J W" uniqKey="Van Der Laan J" first="J. W." last="Van Der Laan">J. W. Van Der Laan</name><affiliation><nlm:aff id="bcp14145-aff-0002"></nlm:aff></affiliation></author><author><name sortKey="Crijns, H J M J" sort="Crijns, H J M J" uniqKey="Crijns H" first="H. J. M. J." last="Crijns">H. J. M. J. Crijns</name><affiliation><nlm:aff id="bcp14145-aff-0002"></nlm:aff></affiliation></author><author><name sortKey="Van Puijenbroek, E P" sort="Van Puijenbroek, E P" uniqKey="Van Puijenbroek E" first="E. P." last="Van Puijenbroek">E. P. Van Puijenbroek</name><affiliation><nlm:aff id="bcp14145-aff-0004"></nlm:aff></affiliation><affiliation><nlm:aff id="bcp14145-aff-0006"></nlm:aff></affiliation></author><author><name sortKey="Van Der Woude, C J" sort="Van Der Woude, C J" uniqKey="Van Der Woude C" first="C. J." last="Van Der Woude">C. J. Van Der Woude</name><affiliation><nlm:aff id="bcp14145-aff-0003"></nlm:aff></affiliation><affiliation><nlm:aff id="bcp14145-aff-0005"></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">31633830</idno><idno type="pmc">7080638</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7080638</idno><idno type="RBID">PMC:7080638</idno><idno type="doi">10.1111/bcp.14145</idno><date when="2020">2020</date><idno type="wicri:Area/Pmc/Corpus">000971</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000971</idno><idno type="wicri:Area/Pmc/Curation">000971</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000971</idno><idno type="wicri:Area/Pmc/Checkpoint">000044</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000044</idno><idno type="wicri:Area/Ncbi/Merge">002463</idno><idno type="wicri:Area/Ncbi/Curation">002463</idno><idno type="wicri:Area/Ncbi/Checkpoint">002463</idno><idno type="wicri:doubleKey">0306-5251:2020:Ghalandari N:the:pre:and</idno><idno type="wicri:Area/Main/Merge">000088</idno><idno type="wicri:Area/Main/Curation">000088</idno><idno type="wicri:Area/Main/Exploration">000088</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">The pre‐ and post‐authorisation data published by the European medicines agency on the use of biologics during pregnancy and lactation</title><author><name sortKey="Ghalandari, N" sort="Ghalandari, N" uniqKey="Ghalandari N" first="N." last="Ghalandari">N. Ghalandari</name><affiliation><nlm:aff id="bcp14145-aff-0001"></nlm:aff></affiliation><affiliation><nlm:aff id="bcp14145-aff-0002"></nlm:aff></affiliation><affiliation><nlm:aff id="bcp14145-aff-0005"></nlm:aff></affiliation></author><author><name sortKey="Dolhain, R J E M" sort="Dolhain, R J E M" uniqKey="Dolhain R" first="R. J. E. M." last="Dolhain">R. J. E. M. Dolhain</name><affiliation><nlm:aff id="bcp14145-aff-0001"></nlm:aff></affiliation><affiliation><nlm:aff id="bcp14145-aff-0005"></nlm:aff></affiliation></author><author><name sortKey="Hazes, J M W" sort="Hazes, J M W" uniqKey="Hazes J" first="J. M. W." last="Hazes">J. M. W. Hazes</name><affiliation><nlm:aff id="bcp14145-aff-0001"></nlm:aff></affiliation><affiliation><nlm:aff id="bcp14145-aff-0002"></nlm:aff></affiliation><affiliation><nlm:aff id="bcp14145-aff-0005"></nlm:aff></affiliation></author><author><name sortKey="Siezen, C L E" sort="Siezen, C L E" uniqKey="Siezen C" first="C. L. E." last="Siezen">C. L. E. Siezen</name><affiliation><nlm:aff id="bcp14145-aff-0002"></nlm:aff></affiliation></author><author><name sortKey="Van Der Laan, J W" sort="Van Der Laan, J W" uniqKey="Van Der Laan J" first="J. W." last="Van Der Laan">J. W. Van Der Laan</name><affiliation><nlm:aff id="bcp14145-aff-0002"></nlm:aff></affiliation></author><author><name sortKey="Crijns, H J M J" sort="Crijns, H J M J" uniqKey="Crijns H" first="H. J. M. J." last="Crijns">H. J. M. J. Crijns</name><affiliation><nlm:aff id="bcp14145-aff-0002"></nlm:aff></affiliation></author><author><name sortKey="Van Puijenbroek, E P" sort="Van Puijenbroek, E P" uniqKey="Van Puijenbroek E" first="E. P." last="Van Puijenbroek">E. P. Van Puijenbroek</name><affiliation><nlm:aff id="bcp14145-aff-0004"></nlm:aff></affiliation><affiliation><nlm:aff id="bcp14145-aff-0006"></nlm:aff></affiliation></author><author><name sortKey="Van Der Woude, C J" sort="Van Der Woude, C J" uniqKey="Van Der Woude C" first="C. J." last="Van Der Woude">C. J. Van Der Woude</name><affiliation><nlm:aff id="bcp14145-aff-0003"></nlm:aff></affiliation><affiliation><nlm:aff id="bcp14145-aff-0005"></nlm:aff></affiliation></author></analytic><series><title level="j">British Journal of Clinical Pharmacology</title><idno type="ISSN">0306-5251</idno><idno type="eISSN">1365-2125</idno><imprint><date when="2020">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec id="bcp14145-sec-0001"><title>Aims</title><p>The effects of biologics on reproduction/lactation are mostly unknown although many patients that receive biologics are women of reproductive age. The first objective of this study was to investigate the publicly available data on pregnancy/lactation before and after marketing authorization in Europe of biologics for the indications of rheumatologic inflammatory autoimmune diseases and inflammatory bowel disease. Secondary objectives included the assessment of the clinical relevance of the provided data and comparison of initial and post‐authorization data.</p></sec><sec id="bcp14145-sec-0002"><title>Methods</title><p>Initial and post‐authorization data were extracted from the European Public Assessment Reports and the latest versions of Summary of Product Characteristics using publicly available documents on the European Medicines Agency's website. Four sections were categorized regarding pregnancy outcomes: pre‐clinical/animal studies, human female fertility, pregnancy‐related outcomes and congenital malformations in the human fetus. Three sections were categorized regarding lactation outcomes: pre‐clinical/animal studies, excretion in human breast milk and absorption in children through breastfeeding. The clinical applicability of each category was scored by specified criteria, based on scientific literature, and further as defined by the authors.</p></sec><sec id="bcp14145-sec-0003"><title>Results</title><p>For the 16 included biologics, post‐authorization data were delivered only for adalimumab, certolizumab pegol, etanercept and infliximab. For the 12 remaining biologics limited data on pregnancy and lactation during the post‐marketing period of 2–21 years were available.</p></sec><sec id="bcp14145-sec-0004"><title>Conclusions</title><p>In this article several suggestions are provided for improving a multidisciplinary approach to these issues. The initiation of suitable registries by marketing authorization holders and data transparency for clinicians and academics are highly endorsed.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct></listBibl></div1></back></TEI><affiliations><list></list><tree><noCountry><name sortKey="Crijns, H J M J" sort="Crijns, H J M J" uniqKey="Crijns H" first="H. J. M. J." last="Crijns">H. J. M. J. Crijns</name><name sortKey="Dolhain, R J E M" sort="Dolhain, R J E M" uniqKey="Dolhain R" first="R. J. E. M." last="Dolhain">R. J. E. M. Dolhain</name><name sortKey="Ghalandari, N" sort="Ghalandari, N" uniqKey="Ghalandari N" first="N." last="Ghalandari">N. Ghalandari</name><name sortKey="Hazes, J M W" sort="Hazes, J M W" uniqKey="Hazes J" first="J. M. W." last="Hazes">J. M. W. Hazes</name><name sortKey="Siezen, C L E" sort="Siezen, C L E" uniqKey="Siezen C" first="C. L. E." last="Siezen">C. L. E. Siezen</name><name sortKey="Van Der Laan, J W" sort="Van Der Laan, J W" uniqKey="Van Der Laan J" first="J. W." last="Van Der Laan">J. W. Van Der Laan</name><name sortKey="Van Der Woude, C J" sort="Van Der Woude, C J" uniqKey="Van Der Woude C" first="C. J." last="Van Der Woude">C. J. Van Der Woude</name><name sortKey="Van Puijenbroek, E P" sort="Van Puijenbroek, E P" uniqKey="Van Puijenbroek E" first="E. P." last="Van Puijenbroek">E. P. Van Puijenbroek</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000088 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000088 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= PMC:7080638
|texte= The pre‐ and post‐authorisation data published by the European medicines agency on the use of biologics during pregnancy and lactation
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:31633830" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a TocilizumabV1
| This area was generated with Dilib version V0.6.34. |  |